BACKGROUND AND OBJECTIVES: Given the paucity of high-quality safety/efficacy data on acute stroke therapies in patients with premorbid disability, they risk being routinely excluded from such therapies. We examined utilization of endovascular thrombectomy (EVT), associated workflow, and poststroke outcomes among patients with vs without premorbid disability. METHODS: We used national registry data on thrombolysis/EVT for the Czech Republic from 1 January 2016 to 31 December 2020. Premorbid disability was defined as prestroke modified Rankin Scale score (mRS) ≥3. We compared proportions of patients with vs without premorbid disability who received EVT and examined workflow times. We compared ΔmRS-change in mRS from prestroke to 3 months-in patients with vs without premorbid disability, in addition to intracerebral hemorrhage (ICH), mortality, and discharge NIHSS (National Institutes of Health Stroke Scale score), adjusting for age, sex, baseline NIHSS, and comorbidities, and verified using propensity score weighting (PSW) and matching for differences in treatment assignment. We stratified by age group (<65, 65-74, 75-84, ≥85 years) to explore outcome heterogeneity with vs without premorbid disability. RESULTS: Among 22,405 patients with ischemic stroke who received thrombolysis/EVT/both, 1,712 (7.6%) had prestroke mRS ≥ 3. Patients with prestroke disability were less likely to receive EVT vs those without (10.1% vs 20.7%, aOR: 0.30, 95% CI 0.24-0.36). When treated, they had longer door-to-arterial puncture times (median: 75 minutes, IQR: 58-100 vs 54, IQR: 27-77, adjusted difference: 12.5, 95% CI 2.68-22.3). Patients with prestroke disability receiving thrombolysis/EVT/both had worse ΔmRS (adjusted rate ratio, aIRR on PSW: 1.57, 95% CI 1.43-1.72), rates of 3-month mRS 5-6, discharge NIHSS, and mortality (aOR-PSW [mortality]: 2.54, 95% CI 1.92-3.34), while ICH did not significantly differ. 32.1% of patients with prestroke disability receiving thrombolysis/EVT/both successfully returned to prestroke state, but this proportion ranged from 19.6% for those older than 85 years to 66.0% for those younger than 65 years. Regardless of premorbid disability, EVT was associated with better outcomes including lower ΔmRS (aIRR-PSW: 0.87, 95% CI 0.83-0.91) and mortality, with no interaction of treatment effect by premorbid disability status (e.g., mortality pinteraction = 0.73). EVT recipients with premorbid disability did not differ significantly for several outcomes including ΔmRS (aIRR: 0.99, 95% CI 0.84-1.17) but were more likely to have 3-month mRS 5-6 (70.1% vs 39.5% without premorbid disability, aOR: 1.85, 95% CI 1.12-3.04). DISCUSSION: Patients with premorbid disability were less likely to receive EVT, had slower treatment times, and had worse outcomes compared with patients without premorbid disability. However, regardless of premorbid disability, patients fared better with EVT vs medical management and one-third with prestroke disability returned to their prestroke status.

• Publikační typ
• časopisecké články MeSH

The safety and efficacy of intravenous thrombolysis (IVT) are well established in anterior circulation stroke (ACS) but are much less clear for posterior circulation stroke (PCS). The aim of this study was to evaluate the occurrence of parenchymal hematoma (PH) and 3-month clinical outcomes after IVT in PCS and ACS. In an observational, cohort multicenter study, we analyzed data from ischemic stroke patients treated with IVT prospectively collected in the SITS (Safe Implementation of Treatments in Stroke) registry in the Czech Republic between 2004 and 2018. Out of 10,211 patients, 1166 (11.4%) had PCS, and 9045 (88.6%) ACS. PH was less frequent in PCS versus ACS patients: 3.6 vs. 5.9%, odds ratio (OR) = 0.594 in the whole set, 4.4 vs. 7.8%, OR = 0.543 in those with large vessel occlusion (LVO), and 2.2 vs. 4.7%, OR = 0.463 in those without LVO. At 3 months, PCS patients compared with ACS patients achieved more frequently excellent clinical outcomes (modified Rankin scale [mRS] 0-1: 55.5 vs. 47.6%, OR = 1.371 in the whole set and 49.2 vs. 37.6%, OR = 1.307 in those with LVO), good clinical outcomes (mRS 0-2: 69.9 vs. 62.8%, OR = 1.377 in the whole set and 64.5 vs. 50.5%, OR = 1.279 in those with LVO), and had lower mortality (12.4 vs. 16.6%, OR = 0.716 in the whole set and 18.4 vs. 25.5%, OR = 0.723 in those with LVO) (p < 0.05 in all cases). In PCS versus ACS patients, an extensive analysis showed a lower risk of PH both in patients with and without LVO, more frequent excellent and good clinical outcomes, and lower mortality 3 months after IVT in patients with LVO.

• Publikační typ
• časopisecké články MeSH

BACKGROUND AND OBJECTIVES: COVID-19-related inflammation, endothelial dysfunction, and coagulopathy may increase the bleeding risk and lower the efficacy of revascularization treatments in patients with acute ischemic stroke (AIS). We aimed to evaluate the safety and outcomes of revascularization treatments in patients with AIS and COVID-19. METHODS: This was a retrospective multicenter cohort study of consecutive patients with AIS receiving intravenous thrombolysis (IVT) and/or endovascular treatment (EVT) between March 2020 and June 2021 tested for severe acute respiratory syndrome coronavirus 2 infection. With a doubly robust model combining propensity score weighting and multivariate regression, we studied the association of COVID-19 with intracranial bleeding complications and clinical outcomes. Subgroup analyses were performed according to treatment groups (IVT-only and EVT). RESULTS: Of a total of 15,128 included patients from 105 centers, 853 (5.6%) were diagnosed with COVID-19; of those, 5,848 (38.7%) patients received IVT-only and 9,280 (61.3%) EVT (with or without IVT). Patients with COVID-19 had a higher rate of symptomatic intracerebral hemorrhage (SICH) (adjusted OR 1.53; 95% CI 1.16-2.01), symptomatic subarachnoid hemorrhage (SSAH) (OR 1.80; 95% CI 1.20-2.69), SICH and/or SSAH combined (OR 1.56; 95% CI 1.23-1.99), 24-hour mortality (OR 2.47; 95% CI 1.58-3.86), and 3-month mortality (OR 1.88; 95% CI 1.52-2.33). Patients with COVID-19 also had an unfavorable shift in the distribution of the modified Rankin score at 3 months (OR 1.42; 95% CI 1.26-1.60). DISCUSSION: Patients with AIS and COVID-19 showed higher rates of intracranial bleeding complications and worse clinical outcomes after revascularization treatments than contemporaneous non-COVID-19 patients receiving treatment. Current available data do not allow direct conclusions to be drawn on the effectiveness of revascularization treatments in patients with COVID-19 or to establish different treatment recommendations in this subgroup of patients with ischemic stroke. Our findings can be taken into consideration for treatment decisions, patient monitoring, and establishing prognosis. TRIAL REGISTRATION INFORMATION: The study was registered under ClinicalTrials.gov identifier NCT04895462.

• MeSH
• cerebrální krvácení komplikace   MeSH
• cévní mozková příhoda * epidemiologie   terapie   diagnóza   MeSH
• COVID-19 * komplikace   MeSH
• endovaskulární výkony * škodlivé účinky   MeSH
• fibrinolytika terapeutické užití   MeSH
• intrakraniální krvácení etiologie   MeSH
• ischemická cévní mozková příhoda * epidemiologie   chirurgie   MeSH
• ischemie mozku * komplikace   epidemiologie   chirurgie   MeSH
• kohortové studie MeSH
• lidé MeSH
• registrace MeSH
• trombolytická terapie škodlivé účinky   MeSH
• výsledek terapie MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• multicentrická studie MeSH
• práce podpořená grantem MeSH

BACKGROUND: Acute ischemic stroke (AIS) due to anterior circulation tandem lesion (TL) remains a technical and clinical challenge for endovascular treatment (EVT). Conflicting results from observational studies and missing evidence from the randomized trials led us to report a recent real-world multicenter clinical experience and evaluate possible predictors of good outcome after EVT. METHODS: We analyzed all AIS patients with TL enrolled in the prospective national study METRICS (Mechanical Thrombectomy Quality Indicators Study in Czech Stroke Centers). A good 3-month clinical outcome was scored as 0-2 points in modified Rankin Scale (mRS), achieved recanalization using the Thrombolysis In Cerebral Infarction (TICI) scale and symptomatic intracerebral hemorrhage (sICH) according to the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST) criteria. RESULTS: Of 1178 patients enrolled in METRICS, 194 (19.2%) (59.8% males, mean age 68.7±11.5 years) were treated for TL. They did not differ in mRS 0-2 (48.7% vs 46.7%; p=0.616), mortality (17.3% vs 22.7%; p=0.103) and sICH (4.7% vs 5.1%; p=0.809) from those with single occlusion (SO). More TL patients with prior intravenous thrombolysis (IVT) reached TICI 3 (70.3% vs 50.8%; p=0.012) and mRS 0-2 (55.4% vs 34.4%; p=0.007) than those without IVT. No difference was found in the rate of sICH (6.2% vs 1.6%; p=0.276). Multivariate logistic regression analysis showed prior IVT as a predictor of mRS 0-2 after adjustment for potential confounders (OR 3.818, 95% CI 1.614 to 9.030, p=0.002). CONCLUSION: Patients with TL did not differ from those with SO in outcomes after EVT. TL patients with prior IVT had more complete recanalization and mRS 0-2 and IVT was found to be a predictor of good outcome after EVT.

• MeSH
• benchmarking MeSH
• cerebrální krvácení etiologie   MeSH
• cévní mozková příhoda * diagnostické zobrazování   chirurgie   MeSH
• endovaskulární výkony * metody   MeSH
• fibrinolytika MeSH
• ischemická cévní mozková příhoda * diagnostické zobrazování   chirurgie   MeSH
• ischemie mozku * diagnostické zobrazování   terapie   etiologie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• prospektivní studie MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• trombektomie škodlivé účinky   MeSH
• trombolytická terapie metody   MeSH
• výsledek terapie MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• multicentrická studie MeSH

Úvod: Dekompresivní kraniektomie (DK) je život zachraňující neurochirurgický výkon s několika technickými možnostmi provedení. Cíl: Cílem této studie bylo porovnat výsledky operační techniky DK s duroplastikou a bez provedené duroplastiky na dvou neurochirurgických pracovištích. Metodika: Retrospektivní bicentrická studie hodnotila výskyt komplikací (tj. infekční, likvorová píštěl, hematom) u jednotlivých technik. Výsledky: Ve studii nebyl prokázán statisticky signifikantně vyšší výskyt komplikací jako jsou infekce (p = 0,539), likvorová píštěl (p = 0,826) či hematom (p = 0,720). V obou sledovaných souborech po kranioplastice nebyly zaznamenány infekční komplikace nebo likvorová píštěl. Komplikace ve formě hematomu byla statisticky nevýznamná (p = 0,155). Byl zjištěn statisticky významný rozdíl v operačním čase kranioplastiky provedené po DK s duroplastikou (medián 53 min) a po DK bez provedené duroplastiky (medián 90 min; p = 0,006). Závěr: DK bez provedení duroplastiky je potenciální bezpečná varianta, která není zatížená vyšším výskytem komplikací ve smyslu infekce nebo vzniku likvorové píštěle a hematomu.

Background: Decompressive craniectomy (DC) is a life-saving neurosurgical procedure with several technical options. Aim: The aim of this study was to compare the results of the DC surgical technique with and without duroplasty performed at two neurosurgery departments. Methods: A retrospective bicentric study evaluated the occurrence of complications (i.e., infection, cerebrospinal fluid fistula, hematoma) in both compared techniques. Results: The study did not demonstrate a statistically significantly higher incidence of complications such as infection (P = 0.539), cerebrospinal fluid fistula (P = 0.826) or hematoma (P = 0.720). No infectious complications or cerebrospinal fluid fistula were recorded in both observed groups after cranioplasty. The complication in the form of hematoma was statistically insignificant (P = 0.155). A statistically significant difference was found in the operative time of cranioplasty performed after DC with duroplasty (median 53 min) and after DC without duroplasty (median 90 min; P = 0.006). Conclusion: DC without duroplasty is a potentially safe option that is not burdened by a higher incidence of complications in terms of infection or the formation of cerebrospinal fluid fistula and hematoma.

• Klíčová slova
• duroplastika, kranioplastika,
• MeSH
• dekompresní kraniektomie metody   MeSH
• lidé MeSH
• retrospektivní studie MeSH
• traumatické poranění mozku * chirurgie   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• práce podpořená grantem MeSH

Autoimmune disease associated with anti-CASPR2 antibodies is a relatively rare neurological illness characterized by the presence of anti-CASPR2 antibodies in serum and/or CSF. It manifests with a variety of symptoms - from the central nervous system (cognitive impairment, epilepsy and cerebellar symptoms), from the peripheral nervous system (peripheral nerve hyperexcitability and neuropathic pain), and from the autonomic nervous system (autonomic dysfunction, insomnia and weight loss). Case report: The 61-year-old patient was admitted to the intensive care unit of our neurological department with myoclonic abdominal muscle twitching with intermittent generalization and right upper limb myoclonus, associated with behavioral change, cognitive deterioration, intermittent disorientation and aggression, bulbar syndrome, dysarthria, and dysautonomia (hypersalivation, bronchial hypersecretion, and circulatory instability). Due to progressive hypercapnia and loss of consciousness, the patient had to be intubated and connected to artificial pulmonary ventilation. EMG investigation demonstrated axonal motor polyneuropathy of both upper and lower limbs. Several unspecific gliotic lesions located in the white matter adjacent to the left cerebral ventricle were described on the brain MRI. Significant anti-CASPR2 antibody positivity was found both in serum and cerebrospinal fluid. Treatment with i.v. methylprednisolone and intravenous immunoglobulins was applied. With this treatment, the patient's neurological status gradually improved to the ability of verticalization. However, his cachectization, which was already present on admission, progressed despite the maximal effort in nutrition therapy. Also, repeated episodes of respiratory insufficiency resulting in transitory impairment of consciousness occurred. One such episode resulted in cardiac arrest followed by successful cardiopulmonary resuscitation. However, myoclonic jerks reappeared afterward and the patient's overall condition worsened. At this stage, it was decided not to further escalate and extend the treatment. Palliative treatment was commenced. The patient died during the following episode of respiratory failure. Comment: This case report of a patient with autoimmune disease associated with anti-CASPR2 antibodies highlights its multiple and often disease-unspecific clinical symptoms on the one hand, and on the other, its severe and ultimately fatal clinical course despite the initial effect of immunotherapy. Early diagnosis and early and aggressive immunomodulatory treatment are crucial in patients with this disorder.

A

u

t

o

i

m

u

n

i

t

n

í

o

n

e

m

o

c

n

ě

n

í

s

p

o

z

i

t

i

v

i

t

o

u

a

n

t

i

­

‐

C

A

S

P

R

2

p

r

o

t

i

l

á

t

e

k

j

e

r

e

l

a

t

i

v

n

ě

v

z

á

c

n

á

c

h

o

r

o

b

a

s

c

h

a

r

a

k

t

e

r

i

s

t

i

c

k

ý

m

n

á

l

e

z

e

m

a

n

t

i

­

‐

C

A

S

P

R

2

p

r

o

t

i

l

á

t

e

k

v

s

é

r

u

,

p

ř

í

p

a

d

n

ě

v

l

i

k

v

o

r

u

.

P

r

o

j

e

v

u

j

e

s

e

ř

a

d

o

u

r

ů

z

n

ý

c

h

s

y

m

p

t

o

m

ů

–

z

c

e

n

t

r

á

l

n

í

h

o

n

e

r

v

o

v

é

h

o

s

y

s

t

é

m

u

(

p

o

r

u

c

h

a

k

o

g

n

i

t

i

v

n

í

c

h

f

u

n

k

c

í

,

e

p

i

l

e

p

s

i

e

a

m

o

z

e

č

k

o

v

é

p

ř

í

z

n

a

k

y

)

,

z

p

e

r

i

f

e

r

n

í

h

o

n

e

r

v

o

v

é

h

o

s

y

s

t

é

m

u

(

h

y

p

e

r

e

x

c

i

t

a

b

i

l

i

t

a

p

e

r

i

f

e

r

n

í

h

o

n

e

r

v

u

a

n

e

u

r

o

p

a

t

i

c

k

á

b

o

l

e

s

t

)

a

z

a

u

t

o

n

o

m

n

í

h

o

n

e

r

v

o

v

é

h

o

s

y

s

t

é

m

u

(

a

u

t

o

n

o

m

n

í

d

y

s

f

u

n

k

c

e

,

i

n

s

o

m

n

i

e

a

z

t

r

á

t

a

h

m

o

t

n

o

s

t

i

)

.

K

a

z

u

i

s

t

i

k

a

:

6

1

l

e

t

ý

p

a

c

i

e

n

t

b

y

l

p

ř

i

j

a

t

n

a

j

e

d

n

o

t

k

u

i

n

t

e

n

z

i

v

n

í

p

é

č

e

n

e

u

r

o

l

o

g

i

c

k

é

h

o

o

d

d

ě

l

e

n

í

p

r

o

m

y

o

k

l

o

n

i

c

k

é

z

á

š

k

u

b

y

a

b

d

o

m

i

n

á

l

n

í

h

o

s

v

a

l

s

t

v

a

s

i

n

t

e

r

m

i

t

e

n

t

n

í

g

e

n

e

r

a

l

i

z

a

c

í

a

m

y

o

k

l

o

n

y

p

r

a

v

é

h

o

r

n

í

k

o

n

č

e

t

i

n

y

,

p

o

r

u

c

h

y

c

h

o

v

á

n

í

,

k

o

g

n

i

t

i

v

n

í

d

e

t

e

r

i

o

r

a

c

i

,

i

n

t

e

r

m

i

t

e

n

t

n

í

d

e

z

o

r

i

e

n

t

a

c

i

a

a

g

r

e

s

i

,

b

u

l

b

á

r

n

í

s

y

n

d

r

o

m

,

d

y

s

a

r

t

r

i

i

a

d

y

s

a

u

t

o

n

o

m

i

i

(

h

y

p

e

r

s

o

m

n

i

i

,

h

y

p

e

r

s

a

l

i

v

a

c

i

,

b

r

o

n

c

h

i

á

l

n

í

h

y

p

e

r

s

e

k

r

e

c

i

a

o

b

ě

h

o

v

o

u

i

n

s

t

a

b

i

l

i

t

u

)

.

P

r

o

p

r

o

g

r

e

s

i

p

o

r

u

c

h

y

v

ě

d

o

m

í

h

y

p

e

r

k

a

p

n

i

c

k

é

e

t

i

o

l

o

g

i

e

m

u

s

e

l

b

ý

t

p

a

c

i

e

n

t

z

a

i

n

t

u

b

o

v

á

n

a

n

a

p

o

j

e

n

n

a

u

m

ě

l

o

u

p

l

i

c

n

í

v

e

n

t

i

l

a

c

i

.

N

a

E

M

G

b

y

l

a

p

r

o

k

á

z

á

n

a

a

x

o

n

á

l

n

í

m

o

t

o

r

i

c

k

á

p

o

l

y

n

e

u

r

o

p

a

t

i

e

s

p

o

s

t

i

ž

e

n

í

m

H

K

K

i

D

K

K

.

N

a

M

R

m

o

z

k

u

b

y

l

o

n

ě

k

o

l

i

k

d

r

o

b

n

ý

c

h

l

o

ž

i

s

e

k

g

l

i

ó

z

y

p

a

r

a

v

e

n

t

r

i

k

u

l

á

r

n

ě

v

l

e

v

o

.

Z

e

s

é

r

a

i

l

i

k

v

o

r

u

b

y

l

a

p

o

t

v

r

z

e

n

a

v

ý

r

a

z

n

á

p

o

z

i

t

i

v

i

t

a

a

n

t

i

­

‐

C

A

S

P

R

2

p

r

o

t

i

l

á

t

e

k

.

P

r

o

d

i

a

g

n

ó

z

u

a

u

t

o

i

m

u

n

i

t

n

í

h

o

o

n

e

m

o

c

n

ě

n

í

b

y

l

a

a

p

l

i

k

o

v

á

n

a

t

e

r

a

p

i

e

v

p

o

d

o

b

ě

i

.

v

.

m

e

t

h

y

l

p

r

e

d

n

i

s

o

l

o

n

u

a

i

n

t

r

a

v

e

n

ó

z

n

í

c

h

i

m

u

n

o

g

l

o

b

u

l

i

n

ů

.

P

a

c

i

e

n

t

ů

v

n

e

u

r

o

l

o

g

i

c

k

ý

s

t

a

v

s

e

p

o

s

t

u

p

n

ě

l

e

p

š

i

l

a

ž

k

e

s

c

h

o

p

n

o

s

t

i

v

e

r

t

i

k

a

l

i

z

a

c

e

,

n

i

c

m

é

n

ě

p

r

o

g

r

e

d

o

v

a

l

a

j

i

ž

j

e

h

o

v

s

t

u

p

n

í

k

a

c

h

e

k

t

i

z

a

c

e

i

p

ř

e

s

m

a

x

i

m

á

l

n

ě

m

o

ž

n

o

u

v

ý

ž

i

v

u

.

O

p

a

k

o

v

a

n

ě

d

o

š

l

o

k

p

o

r

u

c

h

á

m

v

ě

d

o

m

í

n

a

p

o

d

k

l

a

d

ě

r

e

s

p

i

r

a

č

n

í

i

n

s

u

f

i

c

i

e

n

c

e

.

P

ř

i

j

e

d

n

é

z

n

i

c

h

n

a

s

t

a

l

a

i

s

r

d

e

č

n

í

z

á

s

t

a

v

a

s

n

u

t

n

o

s

t

í

k

a

r

d

i

o

p

u

l

m

o

n

á

l

n

í

r

e

s

u

s

c

i

t

a

c

e

.

N

á

s

l

e

d

n

ě

s

e

o

p

ě

t

o

v

n

ě

o

b

j

e

v

i

l

y

m

y

o

k

l

o

n

i

c

k

é

z

á

š

k

u

b

y

.

P

r

o

z

h

o

r

š

e

n

í

c

e

l

k

o

v

é

h

o

s

t

a

v

u

p

a

c

i

e

n

t

a

b

y

l

o

r

o

z

h

o

d

n

u

t

o

o

n

e

r

o

z

š

i

ř

o

v

á

n

í

j

e

h

o

t

e

r

a

p

i

e

s

e

z

a

c

h

o

v

á

n

í

m

m

a

x

i

m

á

l

n

í

h

o

k

o

m

f

o

r

t

u

.

P

ř

i

d

a

l

š

í

m

r

e

s

p

i

r

a

č

n

í

m

s

e

l

h

á

n

í

p

a

c

i

e

n

t

z

e

m

ř

e

l

.

K

o

m

e

n

t

á

ř

:

U

v

e

d

e

n

á

k

a

z

u

i

s

t

i

k

a

p

a

c

i

e

n

t

a

s

a

u

t

o

i

m

u

n

i

t

n

í

m

o

n

e

m

o

c

n

ě

n

í

m

s

p

o

z

i

t

i

v

i

t

o

u

a

n

t

i

­

‐

C

A

S

P

R

2

p

r

o

t

i

l

á

t

e

k

i

l

u

s

t

r

u

j

e

n

a

j

e

d

n

é

s

t

r

a

n

ě

p

e

s

t

r

é

a

č

a

s

t

o

n

e

s

p

e

c

i

f

i

c

k

é

k

l

i

n

i

c

k

é

s

y

m

p

t

o

m

y

t

o

h

o

t

o

o

n

e

m

o

c

n

ě

n

í

,

a

n

a

s

t

r

a

n

ě

d

r

u

h

é

j

e

h

o

z

á

v

a

ž

n

ý

p

r

ů

b

ě

h

,

k

t

e

r

ý

,

i

p

ř

e

s

p

o

č

á

t

e

č

n

í

e

f

e

k

t

i

m

u

n

o

s

u

p

r

e

s

i

v

n

í

l

é

č

b

y

,

s

k

o

n

č

i

l

f

a

t

á

l

n

ě

.

V

č

a

s

n

é

o

d

h

a

l

e

n

í

d

i

a

g

n

ó

z

y

s

p

o

l

u

s

č

a

s

n

o

u

a

a

g

r

e

s

i

v

n

í

i

m

u

n

o

t

e

r

a

p

i

í

j

s

o

u

u

t

ě

c

h

t

o

p

a

c

i

e

n

t

ů

k

l

í

č

o

v

é

.

• MeSH
• autoimunitní nemoci nervového systému * diagnóza   farmakoterapie   imunologie   patologie   MeSH
• autoprotilátky analýza   imunologie   MeSH
• elektroencefalografie metody   MeSH
• elektromyografie metody   MeSH
• glukokortikoidy aplikace a dávkování   terapeutické užití   MeSH
• imunohistochemie metody   MeSH
• intravenózní imunoglobuliny aplikace a dávkování   terapeutické užití   MeSH
• lidé středního věku MeSH
• lidé MeSH
• limbická encefalitida diagnóza   farmakoterapie   imunologie   MeSH
• výsledek terapie MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• Publikační typ
• kazuistiky MeSH

Cíl: Mechanická trombektomie (MT) symptomatického uzávěru mozkové tepny u pacientů s akutní ischemickou cévní mozkovou příhodou (iCMP) se stala standardní léčbou. Cílem studie METRICS (MechanicalThrombectomy Quality Indicators Study in Czech Stroke Centers) bylo ověřit, zda centra v České republice provádějící endovaskulámí léčbu iCMP plní indikátory kvality navržené multioborovým konsenzem, a tak v mezinárodním kontextu ověřit kvalitu péče napříč naší republikou. Metodika: Národní prospektivní observační studie METRICS probíhala v České republice v roce 2019. Studie se zúčastnilo 12 z 15 center provádějících mechanickou trombektomii. Všechna technická a klinická data byla sbírána prospektivně a následně byla srovnána s doporučenými hodnotamijednotlivých parametrů multioborového konsenzu. Výsledky: V práci jsou analyzována data z 12 center, ve kterých bylo mechanickou trombektomii ošetřeno celkem 1178 pacientů (50,3% mužů) s mediánem věku 72 roky (18-98 let). Intravenóznitrombolýzou (IVT) bylo před MT léčeno 827 nemocných (70,2%) a 445 (37,8%) bylo sekundárně transponováno k MT z jiného centra. Získaná data z národní prospektivní observační studie METRICS byla hodnocena pro jednotlivá centra. Shoda výsledků péče s doporučeními navrženými multioborovým konsenzem byla velmi vysoká. Pět center splnilo parametry všech doporučení. Ostatní centra nesplnila pouze ojedinělá kritéria a ve většině případů jen hraničně. Závěr: Výsledky studie METRICS ukazují, že lze splnit doporučované hodnoty parametrů uvedených v mezinárodním multioborovém konsenzu i v podmínkách běžné klinické praxe napříč Českou republikou.

Aim: Mechanical thrombectomy (MT) of symptomatic occlusion of cerebral artery has become a standard treatment in acute ischemic stroke (IS) patients. The aim of the presented study was to evaluate if centers performing endovascular treatment of acute ischemic stroke meet the recommendations established by the international multi-society consensus. Methods: The national prospective observational multicenter study METRICS (Mechanical Thrombectomy Quality Indicators Study in Czech Stroke Centers) was conducted in Czech Republic in year 2019. Twelve of 15 centers performing mechanicaltrombectomy were participating on study. Alltechnicaland clinical data were collected prospectively and achieved results were subsequently compared with the recommendations established by international multi-society consensus. Results: In 12 centers 1178 (86%) patients (50.3% males, median of age 72 years, range 18-98 years) by MT were treated in 2019 and the collected data of these patients were analyzed. IV thrombolysis prior MT was performed in 827 (70.2%) patients and 445 (37.8%) patients were transferred secondarily for MT from primary stroke centers to dedicated comprehensive centers. Achieved data from the study METRICS were subsequently evaluated for individual participating centers. The concordance of results with the recommendations of multi-society consensus was very high. Five centers met parameters of all recommendations. Remaining centers did not meet sporadic criteria only and most parameters had borderline values. Conclusion: The results of METRICS study showed that it is possible meet the recommended values of parameters stated in the international multi-society consensus even in a real world practice across the Czech Republic.

• Klíčová slova
• studie METRICS,
• MeSH
• ischemická cévní mozková příhoda * terapie   MeSH
• lidé MeSH
• mechanická trombolýza metody   MeSH
• prospektivní studie MeSH
• ukazatele kvality zdravotní péče MeSH
• Check Tag
• lidé MeSH

Choroba moyamoya představuje chronické cerebrovaskulární onemocnění vyznačující se progresivní stenózou a/nebo okluzí intrakraniální vnitřní karotidy a jejích proximálních větví se vzniklou abnormální kolaterální sítí drobných tepen. Jestliže vaskulární uzávěr není oboustranný a pacient má diagnostikovanou specifickou základní chorobu, označujeme tento stav jako syndrom moyamoya. Prezentace choroby či syndromu moyamoya v podobě subarachnoidálního krvácení bez nalezeného aneuryzmatu je vzácná. 62letá pacientka byla přijata pro bolesti v oblasti zátylku, krku, čela a spánků trvající 24 hodin. Byla somnolentní, opakovaně zvracela a měla dvojité vidění. Na výpočetní tomografii mozku bylo patrné subarachnoidální krvácení. CT angiografie mozku odhalila uzávěr levé střední mozkové tepny a digitální subtrakční angiografie navíc prokázala síť drobných tortuózních moyamoya cév v povodí levé střední mozkové tepny. Mozková perfuze nebyla nikterak narušena. Pacientka byla přeléčena kortikoidy a byla jí nasazena antiagregační terapie. Diagnóza byla stanovena jako syndrom moyamoya. Propuštěna byla bez neurodeficitu i bez subjektivních potíží. Po šesti letech došlo u pacientky ke zhoršení celkového stavu při probíhající sepsi, na kterou i přes maximální antibiotickou terapii zemřela. Choroba či syndrom moyamoya by měl být zvažován v rámci diferenciální diagnostiky jako příčina subarachnoidálního krvácení, pokud není jako jeho potenciální zdroj nalezena jiná zřejmá cévní patologie.

Choroba či syndrom moyamoya by měl být zvažován v rámci diferenciální diagnostiky jako příčina subarachnoidálního krvácení, pokud není jako jeho potenciální zdroj nalezena jiná zřejmá cévní patologie. Moyamoya disease is a chronic cerebrovascular disease characterized by progressive stenosis and/or occlusion of the intracranial internal carotid and its proximal branches with a created abnormal collateral network of small arteries. If the vascular occlusion is not bilateral and the patient has been diagnosed with a specific underlying illness, we refer to this condition as Moyamoya syndrome. The presentation of Moyamoya disease or syndrome in the form of a non-aneurysmal subarachnoid hemorrhage is rare. The 62-year-old woman was admitted for 24 hours lasting pain in the area of the neck, forehead, and temples. She was somnolent, vomited repeatedly, and had double vision. The brain computed tomography discovered subarachnoid hemorrhage. The brain CT angiography revealed an occlusion of the left middle cerebral artery and the digital subtraction angiography, moreover, showed a network of tiny tortuous moyamoya vessels in the left middle cerebral artery territory. The brain perfusion was not impaired. The patient was treated with corticosteroids and anti-platelet drugs. A diagnosis of Moyamoya syndrome was determined. She was dismissed without neurological deficit or subjective problems. After six years, the patient`s general condition deteriorated because of sepsis, and even after getting maximum antibiotic therapy, she died. Moyamoya disease or syndrome should be considered in the differential diagnosis as the cause of subarachnoid hemorrhage in the absence of other clear vascular pathology as its potential source.

• MeSH
• cévní mozková příhoda diagnóza   etiologie   terapie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• moyamoya nemoc * diagnóza   komplikace   terapie   MeSH
• subarachnoidální krvácení diagnóza   komplikace   terapie   MeSH
• výsledek terapie MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• ženské pohlaví MeSH
• Publikační typ
• kazuistiky MeSH

Koincidence ischemické cévní mozkové příhody a akutního infarktu myokardu není častá, ale ani vzácná. Předkládáme dvě kazuistiky pacientů přijatých do nemocnice pro ischemickou cévní mozkovou příhodu, u kterých za hospitalizace došlo ke vzniku akutního infarktu myokardu s rozdílným finálním výsledkem. 66letá žena byla přijata do nemocnice pro příznaky cévní mozkové příhody v podobě těžké monoparézy levé horní končetiny, centrální parézy levého faciální nervu a dysartrie. Po podání intravenózní trombolýzy došlo k postupnému zlepšení stavu pacientky. Druhého dne se u pacientky objevily stenokardie, opocení, hypotenze, bradykardie a byla stanovena diagnóza akutního infarktu myokardu přední stěny. Po provedení perkutánní koronární intervence došlo ke kompletní regresi pacientčiných potíží. Po celkové sedmidenní hospitalizaci byla pacientka propuštěna s lehkou reziduální parézou dvou prstů levé horní končetiny bez srdečních potíží. 69letý muž byl přijat do nemocnice pro příznaky cévní mozkové příhody v podobě somnolence, levostranné hemiplegie a hemihypestezie, centrální parézy levého faciální nervu, parézy pohledu vlevo, neglect syndromu vlevo a těžké dysartrie. Po podání intravenózní trombolýzy a provedení mechanické trombembolektomie došlo k postupnému zlepšení stavu pacienta. Druhého dne se u pacienta objevily bolesti v epigastriu a byla stanovena diagnóza akutního infarktu myokardu spodní stěny. Po provedení perkutánní koronární intervence došlo k parciální regresi pacientových potíží. Po dvou dnech od kardiologické intervence došlo u pacienta k náhlé srdeční zástavě s neúspěšnou kardiopulmonální resuscitací. Akutní infarkt myokardu komplikující ischemickou cévní mozkovou příhodu přináší pacientům zvýšení morbidity a mortality i přes jeho adekvátní a včasnou diagnostiku a terapii.

Coincidence of ischemic stroke and acute myocardial infarction is not common, but neither it is rare. We present two case reports of patients admitted to hospital for ischemic stroke who have developed acute myocardial infarction with different final outcomes. A 66-year-old woman was admitted to the hospital for symptoms of stroke in the form of severe monoparesis of left upper limb, central left facial nerve paresis, and dysarthria. There was a gradual improvement in the patient's condition after intravenous thrombolysis was administered. The next day, the patient developed stenocardia, sweating, hypotension, and bradycardia and was diagnosed with an acute anterior wall myocardial infarction. Following percutaneous coronary intervention, the patient's symptoms completely regressed. After a total seven-day hospitalization, the patient was released with a mild residual paresis of two fingers of left upper limb without any heart problems. A 69-year-old man was admitted to hospital for symptoms of stroke in the form of somnolence, left-sided hemiplegia and hemihypesthesia, central paresis of the left facial nerve, paresis of the gaze left, neglect of the left-sided syndrome and severe dysarthria. Following intravenous thrombolysis and mechanical thrombectomy, the patient gradually improved. The next day, the patient developed epigastric pain and was diagnosed with acute myocardial infarction of the lower wall. After percutaneous coronary intervention, the patient's problems were partially regressed. Two days after the cardiac intervention, the patient went into sudden cardiac arrest with unsuccessful cardiopulmonary resuscitation. Acute myocardial infarction complicating ischemic stroke causes increase in patients` morbidity and mortality despite adequate and timely diagnosis and therapy.

• MeSH
• infarkt myokardu přední stěny * diagnóza   terapie   MeSH
• infarkt myokardu spodní stěny diagnóza   terapie   MeSH
• ischemická cévní mozková příhoda * diagnóza   terapie   MeSH
• koronární angiografie metody   MeSH
• koronární angioplastika metody   MeSH
• lidé MeSH
• mechanická trombolýza metody   MeSH
• senioři MeSH
• trombolytická terapie metody   MeSH
• výsledek terapie MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• kazuistiky MeSH

BACKGROUND AND PURPOSE: Recent studies suggested an increased incidence of cerebral venous thrombosis (CVT) during the coronavirus disease 2019 (COVID-19) pandemic. We evaluated the volume of CVT hospitalization and in-hospital mortality during the 1st year of the COVID-19 pandemic compared to the preceding year. METHODS: We conducted a cross-sectional retrospective study of 171 stroke centers from 49 countries. We recorded COVID-19 admission volumes, CVT hospitalization, and CVT in-hospital mortality from January 1, 2019, to May 31, 2021. CVT diagnoses were identified by International Classification of Disease-10 (ICD-10) codes or stroke databases. We additionally sought to compare the same metrics in the first 5 months of 2021 compared to the corresponding months in 2019 and 2020 (ClinicalTrials.gov Identifier: NCT04934020). RESULTS: There were 2,313 CVT admissions across the 1-year pre-pandemic (2019) and pandemic year (2020); no differences in CVT volume or CVT mortality were observed. During the first 5 months of 2021, there was an increase in CVT volumes compared to 2019 (27.5%; 95% confidence interval [CI], 24.2 to 32.0; P<0.0001) and 2020 (41.4%; 95% CI, 37.0 to 46.0; P<0.0001). A COVID-19 diagnosis was present in 7.6% (132/1,738) of CVT hospitalizations. CVT was present in 0.04% (103/292,080) of COVID-19 hospitalizations. During the first pandemic year, CVT mortality was higher in patients who were COVID positive compared to COVID negative patients (8/53 [15.0%] vs. 41/910 [4.5%], P=0.004). There was an increase in CVT mortality during the first 5 months of pandemic years 2020 and 2021 compared to the first 5 months of the pre-pandemic year 2019 (2019 vs. 2020: 2.26% vs. 4.74%, P=0.05; 2019 vs. 2021: 2.26% vs. 4.99%, P=0.03). In the first 5 months of 2021, there were 26 cases of vaccine-induced immune thrombotic thrombocytopenia (VITT), resulting in six deaths. CONCLUSIONS: During the 1st year of the COVID-19 pandemic, CVT hospitalization volume and CVT in-hospital mortality did not change compared to the prior year. COVID-19 diagnosis was associated with higher CVT in-hospital mortality. During the first 5 months of 2021, there was an increase in CVT hospitalization volume and increase in CVT-related mortality, partially attributable to VITT.

• Publikační typ
• časopisecké články MeSH